10-Q: Genvor Inc. Reports Q3 2026 Results Amidst Financial Challenges

Genvor Incorporated's Q3 2026 Form 10-Q reveals significant operating losses and a continued lack of revenue, highlighting ongoing concerns about the company's liquidity and ability to continue as a going concern.

Summary

• Genvor Incorporated filed its quarterly report for the period ending June 30, 2026.
• The company reported no revenue for the three and nine months ended June 30, 2026 and 2025.
• Operating expenses for the three months ended June 30, 2026 were $2,481,013, an increase from $577,543 in the prior year period.
• For the nine months ended June 30, 2026, operating expenses were $3,451,160, a decrease from $5,851,013 in the prior year period.
• Net loss for the three months ended June 30, 2026 was $2,556,468 ($0.07 per share), compared to a net loss of $397,779 ($0.01 per share) for the same period in 2025.
• Net loss for the nine months ended June 30, 2026 was $3,562,315 ($0.10 per share), a decrease from $5,698,013 ($0.23 per share) for the same period in 2025.
• The company had $196,522 in cash at June 30, 2026, with a working capital deficit of $2,551,952 and an accumulated deficit of $29,755,621.
• Management has identified material weaknesses in internal control over financial reporting, including lack of oversight, insufficient personnel, and inadequate policies and procedures.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as negative due to the company's continued lack of revenue, significant net losses, and substantial doubt about its ability to continue as a going concern, despite ongoing efforts to secure funding.

Positives

• Net loss for the nine months ended June 30, 2026 decreased by 37.5% to $3,562,315 compared to $5,698,013 in the prior year period.
• Cash provided by financing activities increased to $1,058,248 for the nine months ended June 30, 2026, compared to $498,499 for the same period in 2025.
• The company is developing an AI-enabled peptide platform for agricultural and health applications.
• Milestone payments and stock grants are structured for directors and advisors upon achievement of specific project goals.

Negatives

• The company generated no revenue in the reported periods.
• Significant operating losses continue, with a net loss of $2,556,468 for the three months ended June 30, 2026.
• The company has a substantial accumulated deficit of $29,755,621 as of June 30, 2026.
• There is substantial doubt about the company's ability to continue as a going concern due to insufficient cash to cover operating expenses for the next twelve months.
• Material weaknesses in internal control over financial reporting have been identified and are not yet remediated.
• The company has significant debt obligations, including convertible notes and related party advances.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital.
• Failure to raise additional capital may require the company to delay, reduce, or eliminate elements of its business plan.
• The company has not generated any revenue and has a limited operating history.
• The company is subject to risks related to the development and commercialization of its AI-enabled BioCypher platform and peptide solutions.
• Advancement in technologies and changes in demand for peptide-based solutions pose risks.
• Intellectual property risks, including the ability to protect intellectual property, are present.
• The company faces risks related to its reliance on third-party organizations.
• The company has identified material weaknesses in its internal control over financial reporting, which could lead to misstatements in financial statements.

Future Outlook

The company expects its research and development expenses to increase as it advances testing and validation of its peptide candidates and continues to develop its BioCypher platform. The company's continued growth is dependent upon obtaining additional financing to fund future obligations and pay liabilities. Management intends to seek additional funding through public or private offerings of equity or debt securities, strategic relationships, or other arrangements.

Management Comments

• Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
• Management has updated its internal processes and controls to strengthen their effectiveness and developed a remediation plan.
• Management can give no assurance that such capital will be raised or that these measures will be implemented on the timeline currently contemplated.
• We will not be able to conclude that the material weaknesses have been remediated until the applicable controls have been fully implemented, have operated for a sufficient period of time, and management has concluded, through testing, that such controls are operating effectively.

Industry Context

StockSavvy.ai notes that Genvor's focus on an AI-enabled peptide platform for agriculture and health aligns with growing industry trends towards sustainable solutions and precision biotechnology. However, the company faces significant challenges in execution and funding compared to established players in the ag-tech and biotech sectors.

Comparison to Industry Standards

• The company has not generated revenue, which is a significant deviation from industry standards for companies seeking to commercialize products in the agricultural and health sectors.
• The substantial accumulated deficit and ongoing net losses are common for early-stage biotech and ag-tech companies, but the lack of a clear path to revenue and the going concern warning are critical concerns.
• The identified material weaknesses in internal controls are a significant concern and contrast with the robust financial reporting and governance expected of publicly traded companies in the sector.

Corporate Governance

Legal Proceedings

• The Company filed suit against Justin Kimbrough and Prosperity Consultants, LLC, alleging fraud and other causes of action related to improper receipt of shares. A settlement was reached requiring Mr. Kimbrough to return shares, and 331,250 shares were cancelled on October 22, 2025.
• The Company filed suit against Richard Saied, alleging fraud and other causes of action related to improper receipt of shares.
• The Company's former Chief Business Officer and Interim Chief Financial Officer sent a letter demanding payment for amounts claimed under her prior employment agreement; the Company disputes the allegations.

Related Party Transactions

• Accrued compensation and advances from the Company's CEO and two scientific advisors (who are also directors) bear interest at 8%.
• The CEO's employment agreement was amended to increase salary, establish a guaranteed bonus, and provide for quarterly stock grants.
• The scientific advisors' aggregate monthly compensation was increased.
• An Acting Chief Financial Officer services agreement includes current and deferred cash compensation, with deferred compensation payable by December 31, 2026, or later if payment would jeopardize the company's going concern status.
• A Board-approved Tax Reimbursement Policy, effective retroactively to January 1, 2024, covers income taxes, penalties, and interest for the CEO and two directors on compensation derived from the Company.
• The Company owes $84,137 in advances from related parties (scientific advisors) as of June 30, 2026.

Stakeholder Impact

• Shareholders: Continued net losses and the going concern warning negatively impact shareholder value. The potential for a reverse stock split could affect share price perception.
• Employees: The company is incurring significant compensation and related expenses, including under a tax reimbursement policy for key personnel.
• Creditors: The company has outstanding convertible notes and other liabilities, and its ability to meet obligations is dependent on future financing.
• Management: Faces challenges in remediating internal control weaknesses and securing necessary funding.

Next Steps

• Continue to advance testing and validation of peptide candidates and develop the BioCypher platform.
• Seek additional financing through public or private offerings of equity or debt securities, strategic relationships, or other arrangements.
• Implement remediation plan for material weaknesses in internal control over financial reporting.
• The Board of Directors will continue to monitor the status of remediation efforts quarterly.
• The company's board of directors and shareholders approved the adoption of the 2026 Omnibus Equity Incentive Plan and the authority to effect a reverse stock split.

Key Dates

Recommendation

The company continues to operate without revenue, incurring significant losses and facing substantial doubt about its ability to continue as a going concern. Despite efforts to raise capital and develop its technology, the financial situation and identified material weaknesses in internal controls present a high level of risk for investors.

Keywords

peptide platform, AI-enabled, BioCypher, agricultural crop protection, human health, wellness applications, antimicrobial peptide, Form 10-Q